Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge
- PMID: 16243151
- DOI: 10.1016/j.jaad.2005.07.030
Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge
Abstract
In 44 patients treated with arsenic trioxide (As2(O3)) for acute promyelocytic leukemia, 11 developed varicella zoster virus (VZV) reactivation (median 56 days [range 15-299]) after treatment. There was no preferential dermatome involvement or systemic spread. The actuarial risk of VZV reactivation at 1 year was 26%. No VZV reactivation occurred after the first year of initial treatment with As2(O3).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
